Targeting mutant p53 with arsenic trioxide: A preclinical study focusing on triple negative breast cancer
-
Published:2024-08
Issue:
Volume:46
Page:102025
-
ISSN:1936-5233
-
Container-title:Translational Oncology
-
language:en
-
Short-container-title:Translational Oncology
Author:
Rajaram SubhasreeORCID,
Synnott Naoise C.,
Crown John,
Madden Stephen F.,
Duffy Michael J.
Reference42 articles.
1. Treatment landscape of triple-negative breast cancer–expanded options, evolving needs;Bianchini;Nat. Rev. Clin. Oncol.,2022
2. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer;Schmid;N. Engl. J. Med.,2018
3. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response;Loibl;Ann. Oncol.,2022
4. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial;Schmid;Lancet Oncol.,2020
5. Pembrolizumab plus chemotherapy in triple-negative breast cancer;Masuda;Lancet,2021